Market Place
Sourcing Support
Outlook Therapeutics Finalizes $5.0M Public Offering
25 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Announces Proposed Public Offering
23 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Unveils $18.4M Non-Convertible Note
16 Mar 2026 //
GLOBENEWSWIRE
Outlook Updates On FDA Meeting Regarding ONS-5010/LYTENAVA
05 Mar 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q1 FY2026 Results and Corporate
17 Feb 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Seeks FDA Type A Meeting Post-CRL Letter
11 Feb 2026 //
GLOBENEWSWIRE
Outlook Therapeutics Updates FDA Review Of ONS-5010 For Wet AMD
31 Dec 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Announces New Employment Inducement Grants
26 Dec 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Unveils Fiscal Year 2025 Financial Results
19 Dec 2025 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At Piper Sandler Healthcare Conf
24 Nov 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Accepts FDA`s ONS-5010 BLA For Wet AMD
13 Nov 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Resubmits BLA For ONS-5010
03 Nov 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Provides Update On Type A Meeting With FDA
29 Sep 2025 //
GLOBENEWSWIRE
Outlook Therapeutics to Showcase at 2025 EURETINA Innovation
03 Sep 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Requests Type A Meeting with FDA
02 Sep 2025 //
GLOBENEWSWIRE
Outlook Provides FDA Review Update on ONS-5010 for Wet AMD
28 Aug 2025 //
GLOBENEWSWIRE
Outlook Therapeutics at Ophthalmology Innovation Summit Showcase
24 Jul 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Announces SMC Recommendation of Lytenava
10 Jun 2025 //
GLOBENEWSWIRE
Outlook Launches Lytenava in Germany and UK for Wet AMD
02 Jun 2025 //
GLOBENEWSWIRE
Outlook Therapeutics®: FDA Accepts ONS-5010 BLA for Wet AMD
08 Apr 2025 //
GLOBENEWSWIRE
Outlook Therapeutics Re-Submits BLA For ONS-5010 In Wet AMD
28 Feb 2025 //
GLOBENEWSWIRE
Outlook Joins Virtual Investor “Top 5 for ‘25” Conference
19 Feb 2025 //
GLOBENEWSWIRE
Outlook Therapeutics® Streamlines Operations
13 Dec 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Announces NICE Approval for LYTENAVA™
04 Dec 2024 //
GLOBENEWSWIRE
Outlook`s eye disease drug fails to match Lucentis, sinking stock
30 Nov 2024 //
FIERCE BIOTECH
Outlook Therapeutics Attends Chardan Virtual Ophthalmology Conference
13 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Completes NORSE EIGHT Trial Enrollment
04 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q3 FY 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At BTIG Virtual Biotechnology Conference
30 Jul 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Announces UK MHRA Approval Of LYTENAVA™ For Wet AMD
08 Jul 2024 //
GLOBENEWSWIRE
Outlook Therapeutics: EU Approval For LYTENAVA Wet AMD Treatment
28 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q2 Fiscal 2024 Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year
14 Feb 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
31 Jan 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023
22 Dec 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Submits SPA to FDA for Non-Inferiority Study of ONS-5010
19 Dec 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes
27 Nov 2023 //
GLOBENEWSWIRE
Outlook to conduct another trial for wet AMD drug; Cara strikes new royalty deal
03 Nov 2023 //
ENDPTS
Outlook Therapeutics Reports Financial Results for Q3 Fiscal Year 2023
14 Aug 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for 2Q Fiscal Year 2023
15 May 2023 //
GLOBENEWSWIRE
